A Fatality Due to the Intranasal Abuse of Methylphenidate (Ritalin®)

Abstract
A fatality in a teenager from the recreational intranasal abuse of methylphenidate (Ritalin®) is reported. The prescribed use of methylphenidate (Ritalin®) in the treatment of attention deficit and/or hyperactivity disorder is widespread. The intranasal abuse of methylphenidate (Ritalin®) among teenagers is becoming increasingly more recognized. Previous deaths from the parenteral abuse of methylphenidate (Ritalin®) have been reported. This fatality is the first reported from its intranasal abuse.

This publication has 13 references indexed in Scilit: